Literature DB >> 24410722

DNA-aptamer targeting vimentin for tumor therapy in vivo.

Tatyana N Zamay1, Olga S Kolovskaya, Yury E Glazyrin, Galina S Zamay, Svetlana A Kuznetsova, Ekaterina A Spivak, Mohamed Wehbe, Anna G Savitskaya, Olga A Zubkova, Anastasia Kadkina, Xiaoyan Wang, Darija Muharemagic, Anna Dubynina, Yuliya Sheina, Alla B Salmina, Maxim V Berezovski, Anna S Zamay.   

Abstract

In recent years, new prospects for the use of nucleic acids as anticancer drugs have been discovered. Aptamers for intracellular targets can regulate cellular functions and cause cell death or proliferation. However, intracellular aptamers have limited use for therapeutic applications due to their low bioavailability. In this work, we selected DNA aptamers to cell organelles and nucleus of cancer cells, and showed that an aptamer NAS-24 binds to vimentin and causes apoptosis of mouse ascites adenocarcinoma cells in vitro and in vivo. To deliver the aptamer NAS-24 inside cells, natural polysaccharide arabinogalactan was used as a carrier reagent. The mixture of arabinogalactan and NAS-24 was injected intraperitonealy for 5 days into mice with adenocarcinoma and inhibited adenocarcinoma growth more effectively than free arabinogalactan or the aptamer alone. The use of aptamers to intracellular targets together with arabinogalactan becomes a promising approach for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24410722      PMCID: PMC3962644          DOI: 10.1089/nat.2013.0471

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  48 in total

1.  Lectins and glycoconjugates in drug delivery and targeting.

Authors:  Claus-Michael Lehr; Franz Gabor
Journal:  Adv Drug Deliv Rev       Date:  2004-03-03       Impact factor: 15.470

Review 2.  The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery.

Authors:  Franz Gabor; Elisabeth Bogner; Andrea Weissenboeck; Michael Wirth
Journal:  Adv Drug Deliv Rev       Date:  2004-03-03       Impact factor: 15.470

3.  Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes.

Authors:  Karen Sellins; Lee Fradkin; Denny Liggitt; Steven Dow
Journal:  Mol Ther       Date:  2005-09       Impact factor: 11.454

4.  Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis.

Authors:  J Valladeau; V Duvert-Frances; J J Pin; M J Kleijmeer; S Ait-Yahia; O Ravel; C Vincent; F Vega; A Helms; D Gorman; S M Zurawski; G Zurawski; J Ford; S Saeland
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

5.  Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis.

Authors:  Y Byun; F Chen; R Chang; M Trivedi; K J Green; V L Cryns
Journal:  Cell Death Differ       Date:  2001-05       Impact factor: 15.828

Review 6.  RNA aptamers: from basic science towards therapy.

Authors:  H Ulrich
Journal:  Handb Exp Pharmacol       Date:  2006

Review 7.  Gene therapy and reproductive medicine.

Authors:  John M Stribley; Khurram S Rehman; Hairong Niu; Gregory M Christman
Journal:  Fertil Steril       Date:  2002-04       Impact factor: 7.329

8.  Transactivation of vimentin by beta-catenin in human breast cancer cells.

Authors:  Christine Gilles; Myriam Polette; Mélanie Mestdagt; Béatrice Nawrocki-Raby; Philippe Ruggeri; Philippe Birembaut; Jean-Michel Foidart
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Association of Vimentin overexpression and hepatocellular carcinoma metastasis.

Authors:  Liang Hu; Sze Hang Lau; Chi-Hung Tzang; Jian-Ming Wen; Weisheng Wang; Dan Xie; Minghui Huang; Yi Wang; Meng-Chao Wu; Jie-Fu Huang; Wei-Fen Zeng; Jonathan S T Sham; Mengsu Yang; Xin-Yuan Guan
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

10.  The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?

Authors:  Eberhard Korsching; Jens Packeisen; Cornelia Liedtke; Daniela Hungermann; Pia Wülfing; Paul J van Diest; Burkhard Brandt; Werner Boecker; Horst Buerger
Journal:  J Pathol       Date:  2005-08       Impact factor: 7.996

View more
  14 in total

1.  Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease.

Authors:  Rajeev K Chaudhary; Kinjal A Patel; Milan K Patel; Radha H Joshi; Ipsita Roy
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

2.  Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.

Authors:  Rezvan Yazdian-Robati; Mohammad Ramezani; Seyed Hamid Jalalian; Khalil Abnous; Seyed Mohammad Taghdisi
Journal:  Pharm Res       Date:  2016-06-09       Impact factor: 4.200

3.  Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.

Authors:  Hongyu Wang; Xin Li; David E Volk; Ganesh L-R Lokesh; Miguel-Angel Elizondo-Riojas; Li Li; Alpa M Nick; Anil K Sood; Kevin P Rosenblatt; David G Gorenstein
Journal:  Biotechniques       Date:  2016-11-01       Impact factor: 1.993

Review 4.  Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.

Authors:  Dongxi Xiang; Sarah Shigdar; Greg Qiao; Tao Wang; Abbas Z Kouzani; Shu-Feng Zhou; Lingxue Kong; Yong Li; Chunwen Pu; Wei Duan
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

5.  Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.

Authors:  Galina S Zamay; Olga S Kolovskaya; Tatiana N Zamay; Yury E Glazyrin; Alexey V Krat; Olga Zubkova; Ekaterina Spivak; Mohammed Wehbe; Ana Gargaun; Darija Muharemagic; Mariia Komarova; Valentina Grigorieva; Andrey Savchenko; Andrey A Modestov; Maxim V Berezovski; Anna S Zamay
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

Review 6.  Aptamers: A promising chemical antibody for cancer therapy.

Authors:  Gang Zhou; George Wilson; Lionel Hebbard; Wei Duan; Christopher Liddle; Jacob George; Liang Qiao
Journal:  Oncotarget       Date:  2016-03-22

Review 7.  Aptamer Therapeutics in Cancer: Current and Future.

Authors:  Yoshihiro Morita; Macall Leslie; Hiroyasu Kameyama; David E Volk; Takemi Tanaka
Journal:  Cancers (Basel)       Date:  2018-03-19       Impact factor: 6.639

Review 8.  Targeted Magnetic Nanotheranostics of Cancer.

Authors:  Irina Belyanina; Olga Kolovskaya; Sergey Zamay; Ana Gargaun; Tatiana Zamay; Anna Kichkailo
Journal:  Molecules       Date:  2017-06-12       Impact factor: 4.411

Review 9.  Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application.

Authors:  Tatsuo Adachi; Yoshikazu Nakamura
Journal:  Molecules       Date:  2019-11-21       Impact factor: 4.411

Review 10.  Vimentin Diversity in Health and Disease.

Authors:  Frida Danielsson; McKenzie Kirsten Peterson; Helena Caldeira Araújo; Franziska Lautenschläger; Annica Karin Britt Gad
Journal:  Cells       Date:  2018-09-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.